Close Menu

NEW YORK – Investment bank Cowen on Thursday initiated coverage of DermTech with a rating of Outperform and price target of $20.

In a note, analyst Ryan Blicker lauded the company's noninvasive test for early melanoma detection, PLA, which uses a proprietary adhesive patch sampling technology to measure aberrant gene expression in suspect skin lesions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.